PARP inhibitors such as Olaparib [32,33], Rucaparib [34], and Niraparib [35] have been approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated ovarian cancer in different settings [36]. Here, PARP1 is linked to ovarian carcinoma.